Vir Biotechnology (VIR) Asset Utilization Ratio (2019 - 2026)
Vir Biotechnology (VIR) posted Asset Utilization Ratio of 0.06 for Q1 2026, down 4.67% sequentially from 0.07 in Q4 2025, and up 319.29% YoY from 0.02 in Q1 2025.
Vir Biotechnology (VIR) Asset Utilization Ratio (2019 - 2026) Analysis & Trends
Vir Biotechnology has reported Asset Utilization Ratio for 8 years, with the latest figure at 0.06 in Q1 2026.
- Quarterly Asset Utilization Ratio rose 319.29% year-over-year to 0.06 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.06 (up 319.29% YoY) and the FY2025 annual result came in at 0.06, up 27.63% from the prior year.
- Asset Utilization Ratio retreated to 0.06 in Q1 2026 per VIR's latest filing, from 0.07 in the prior quarter.
- Over five years, Asset Utilization Ratio peaked at 0.96 in Q1 2022 and troughed at 0.02 in Q2 2025.
- A 5-year average of 0.24 and a median of 0.06 in 2023 frame the typical range for Asset Utilization Ratio.
- The sharpest annual moves came in 2022 and 2023: Asset Utilization Ratio surged 1909.12% in 2022, then sank 94.02% in 2023.
- Over 5 years, Asset Utilization Ratio stood at 0.62 in 2022, then tumbled by 92.96% to 0.04 in 2023, then rose by 10.39% to 0.05 in 2024, then surged by 41.26% to 0.07 in 2025, then retreated by 4.67% to 0.06 in 2026.
- According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.06, 0.07, and 0.02 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.69 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 186.67 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.13 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.90 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.54 |
| 10 | Vir Biotechnology | 1.56 Bn | 1.56 Bn | 238.95 Mn | 0.27 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.27 |
| Mar 31, 2026 | 0.06 |
| Dec 31, 2025 | 0.07 |
| Sep 30, 2025 | 0.02 |
| Jun 30, 2025 | 0.02 |
| Mar 31, 2025 | 0.02 |
| Dec 31, 2024 | 0.05 |
| Sep 30, 2024 | 0.05 |
| Jun 30, 2024 | 0.04 |
| Mar 31, 2024 | 0.04 |
| Dec 31, 2023 | 0.04 |
| Sep 30, 2023 | 0.06 |
| Jun 30, 2023 | 0.20 |
| Mar 31, 2023 | 0.19 |
| Dec 31, 2022 | 0.62 |
| Sep 30, 2022 | 0.93 |
| Jun 30, 2022 | 0.80 |
| Mar 31, 2022 | 0.96 |
| Dec 31, 2021 | 0.69 |
| Sep 30, 2021 | 0.24 |